Minnesota Oncology

Ovarian Cancer News

Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer (April 9, 2014)

The addition of Avastin® (bevacizumab) to standard chemotherapy significantly improved progression-free survival and objective response rate among women with platinum-resistant recurrent ovarian cancer, according to the results of a study published early... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine (January 30, 2014)

Treatment with Dacogen® (decitabine) prior to the administration of Adriamycin® (doxorubicin) and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, according to a study published in Cancer Immunology Research. Ovarian... Continue Reading

Oral Contraceptives and the Risk of Breast and Ovarian Cancer (November 20, 2013)

Women with BRCA 1/2 mutations who use oral contraceptives (birth control pills) have a significantly reduced risk of ovarian cancer and a non-significantly increased risk of breast cancer, according to the results of a study published in the Journal... Continue Reading

Cediranib Improves Survival in Recurrent Ovarian Cancer (October 21, 2013)

Women with recurrent ovarian cancer experienced significantly improved survival when they received targeted agent cediranib with chemotherapy and as maintenance therapy after chemotherapy, according to the results of a study presented at the ESMO 2013... Continue Reading

Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer (September 18, 2013)

Dose-dense paclitaxel plus carboplatin was associated with significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer, according to the... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Ovarian Cancer Rates Appeared to Drop Along with a Drop in the Use of Hormone Replacement Therapy (June 21, 2013)

Ovarian rates began to decline faster in 2002, which is about the same time many older women stopped using hormone replacement therapy, according to the results of a study published in the Journal of Clinical Oncology. Hormone replacement therapy (HRT)... Continue Reading

Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer (June 13, 2013)

In a Phase III clinical trial, treatment with Votrient® (pazopanib) after initial chemotherapy improved outcomes among women with advanced ovarian cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

Novel Two-step Immunotherapy Shows Promise in Recurrent Ovarian Cancer (May 17, 2013)

A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, according to data from two phase I clinical trials presented at the American Association for Cancer Research (AACR) Annual Meeting... Continue Reading

Latest Ovarian Cancer News By Stage


Recurrent Ovarian Cancer

Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer (April 9, 2014)

The addition of Avastin® (bevacizumab) to standard chemotherapy significantly improved progression-free survival and objective response rate among women with platinum-resistant recurrent ovarian cancer, according to the results of a study published early... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine (January 30, 2014)

Treatment with Dacogen® (decitabine) prior to the administration of Adriamycin® (doxorubicin) and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, according to a study published in Cancer Immunology Research. Ovarian... Continue Reading

Cediranib Improves Survival in Recurrent Ovarian Cancer (October 21, 2013)

Women with recurrent ovarian cancer experienced significantly improved survival when they received targeted agent cediranib with chemotherapy and as maintenance therapy after chemotherapy, according to the results of a study presented at the ESMO 2013... Continue Reading

Novel Two-step Immunotherapy Shows Promise in Recurrent Ovarian Cancer (May 17, 2013)

A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, according to data from two phase I clinical trials presented at the American Association for Cancer Research (AACR) Annual Meeting... Continue Reading

More Recurrent Ovarian Cancer

Screening/Prevention Ovarian Cancer

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Oral Contraceptives and the Risk of Breast and Ovarian Cancer (November 20, 2013)

Women with BRCA 1/2 mutations who use oral contraceptives (birth control pills) have a significantly reduced risk of ovarian cancer and a non-significantly increased risk of breast cancer, according to the results of a study published in the Journal... Continue Reading

Ovarian Cancer Rates Appeared to Drop Along with a Drop in the Use of Hormone Replacement Therapy (June 21, 2013)

Ovarian rates began to decline faster in 2002, which is about the same time many older women stopped using hormone replacement therapy, according to the results of a study published in the Journal of Clinical Oncology. Hormone replacement therapy (HRT)... Continue Reading

Ovarian Cancer Rates Declining in Breast Cancer Survivors (February 7, 2013)

The rate of second primary ovarian cancers after first primary breast cancer appears to be on the decline, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed... Continue Reading

Diabetes Drug May Help Prevent or Treat Ovarian Cancer (December 3, 2012)

Metformin, a widely prescribed insulin-lowering drug for diabetes, has been associated with survival in ovarian cancer and is worthy of further study, as it may be considered for the prevention or treatment of ovarian cancer, according to the results... Continue Reading

More Screening/Prevention Ovarian Cancer

Stage I Ovarian Cancer

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Ovarian Cancer Rates Declining in Breast Cancer Survivors (February 7, 2013)

The rate of second primary ovarian cancers after first primary breast cancer appears to be on the decline, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed... Continue Reading

Diabetes Drug May Help Prevent or Treat Ovarian Cancer (December 3, 2012)

Metformin, a widely prescribed insulin-lowering drug for diabetes, has been associated with survival in ovarian cancer and is worthy of further study, as it may be considered for the prevention or treatment of ovarian cancer, according to the results... Continue Reading

Treatment at High-Volume Hospitals Leads to Lower Mortality Rates for Ovarian Patients (November 20, 2012)

Ovarian cancer patients who undergo surgery at high-volume hospitals have better outcomes than those who are treated at low-volume hospitals, according to the results of a study published in the Journal of Clinical Oncology. This is the result not of... Continue Reading

Gene Helps Predict Response to Chemotherapy in Ovarian Cancer (September 28, 2012)

Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Journal of Cancer. Each year in the United States,... Continue Reading

More Stage I Ovarian Cancer

Stage II-IV Ovarian Cancer

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine (January 30, 2014)

Treatment with Dacogen® (decitabine) prior to the administration of Adriamycin® (doxorubicin) and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, according to a study published in Cancer Immunology Research. Ovarian... Continue Reading

Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer (September 18, 2013)

Dose-dense paclitaxel plus carboplatin was associated with significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer, according to the... Continue Reading

Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer (June 13, 2013)

In a Phase III clinical trial, treatment with Votrient® (pazopanib) after initial chemotherapy improved outcomes among women with advanced ovarian cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

Delaying Chemotherapy Increases Mortality in Ovarian Cancer (April 12, 2013)

Women with advanced ovarian cancer have significantly worse survival when they wait more than 25 days after surgery to start chemotherapy, according to the results of a study presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s... Continue Reading

More Stage II-IV Ovarian Cancer